Stock KHTRF KNIGHT THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Knight Therapeutics Inc. OTC Markets

Equities

KHTRF

CA4990531069

Delayed OTC Markets
Other stock markets
 03:31:51 2024-06-24 pm EDT 		5-day change 1st Jan Change
3.97 USD -4.57% Intraday chart for Knight Therapeutics Inc. -4.57% +0.25%
May. 09 Knight Therapeutics Up Near 3% After Announcing Supply and Distribution Agreement For ADHD Medication; Despite Mixed Q1 MT
May. 09 Transcript : Knight Therapeutics Inc., Q1 2024 Earnings Call, May 09, 2024

Evolution of the average Target Price on Knight Therapeutics Inc.

Price target over the last 5 years

History of analyst recommendation changes

adc065c75104293a795356ad9a4.erj8_xHp_B_NiaKP2br3M975x2Pc-tX0VDMp6EJihIY.T9qmh06wzlyjuOHtkvSWZbbNpBe_nIrFA3IfniwF0cwpzZivfKKybof_6w~bf7f5379170f8b1f1e8caa81d4cbef0c

Analyst Recommendations on Knight Therapeutics Inc.

Knight Therapeutics Price Target Raised to $7 at RBC MT
National Bank Downgrades Knight Therapeutics to Sector Perform, Cuts Price Target to $6, on "Soft" Outlook MT
Knight Therapeutics Hold Rating Maintained by Stifel GMP as Q2 Results Beat Forecasts; Price Target Raised to C$5.40 MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
5.48 CAD
Average target price
7.243 CAD
Spread / Average Target
+32.17%
High Price Target
8 CAD
Spread / Highest target
+45.99%
Low Price Target
5.75 CAD
Spread / Lowest Target
+4.93%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Knight Therapeutics Inc.

RBC Capital Markets
National Bank
Stifel GMP

Ratings for Knight Therapeutics Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. GUD Stock
  4. KHTRF Stock
  5. Consensus Knight Therapeutics Inc.